Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GSD CVE:LTY CVE:RVV TSE:RVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSDGlobal System Dynamics$11.11$11.16$9.90▼$11.98$36.77MN/A7,280 shs2 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsRVVRevive TherapeuticsC$0.08+14.3%C$0.08C$0.07▼C$0.25C$5.79MN/A93,085 shs212,852 shsRVXResverlogixC$0.10+11.1%C$0.07C$0.04▼C$0.30C$19.79M0.71112,881 shs284,726 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSDGlobal System Dynamics0.00%0.00%0.00%0.00%0.00%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%RVVRevive Therapeutics0.00%0.00%0.00%0.00%0.00%RVXResverlogix0.00%-23.08%+100.00%+122.22%+81.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSDGlobal System DynamicsN/AN/AN/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSDGlobal System Dynamics 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/ARVVRevive Therapeutics 0.00N/AN/AN/ARVXResverlogix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSDGlobal System DynamicsN/AN/AN/AN/A($1.84) per shareN/ALTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/ARVVRevive TherapeuticsN/AN/AC$0.03 per share3.18C$0.02 per shareN/ARVXResverlogixN/AN/AC$0.00 per share132.50C($0.23) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSDGlobal System Dynamics-$790KN/A0.00∞N/AN/AN/A-2.30%N/ALTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/ARVVRevive TherapeuticsN/A-C$0.02N/A∞N/AN/AN/AN/AN/ARVXResverlogix-C$2.81M-C$0.02N/A∞N/AN/A6.06%-34.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSDGlobal System DynamicsN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/ARVXResverlogixN/A7.02%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSDGlobal System DynamicsN/A0.010.01LTYLiberty Biopharma8.190.120.12RVVRevive TherapeuticsN/A6.146.03RVXResverlogix-10.950.130.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSDGlobal System Dynamics24.82%LTYLiberty BiopharmaN/ARVVRevive TherapeuticsN/ARVXResverlogixN/AInsider OwnershipCompanyInsider OwnershipGSDGlobal System Dynamics62.81%LTYLiberty BiopharmaN/ARVVRevive TherapeuticsN/ARVXResverlogix42.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSDGlobal System DynamicsN/A3.31 million1.23 millionNot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableRVVRevive TherapeuticsN/A72.41 millionN/ANot OptionableRVXResverlogix19197.94 millionN/ANot OptionableRVV, GSD, LTY, and RVX HeadlinesRecent News About These CompaniesResverlogix Corp.: Resverlogix Announces Voting Results from the 2025 Meeting of ShareholdersJune 30, 2025 | finanznachrichten.deResverlogix Announces Voting Results from the 2025 Meeting of ShareholdersJune 30, 2025 | finance.yahoo.comNew beanless 'coffee' emerges but does it taste any good?September 17, 2024 | bbc.comBNumerous Independent Groups Presented Data that Supports Apabetalone’s Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024September 3, 2024 | msn.comResverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)September 3, 2024 | theglobeandmail.comResverlogix Corp. (RVXCF)July 31, 2024 | finance.yahoo.comResverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture ExtensionJuly 31, 2024 | finance.yahoo.comClosing Bell: Resverlogix Corp up on Tuesday (RVX)July 28, 2024 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Wednesday (RVX)July 25, 2024 | theglobeandmail.comResverlogix Announces Updated Annual and Special Meeting of ShareholdersMay 28, 2024 | finance.yahoo.comResverlogix Corp. (RVX.TO)May 16, 2024 | finance.yahoo.comResverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion PrivilegesMay 13, 2024 | finance.yahoo.comResverlogix Announces Change to Its Board of DirectorsFebruary 21, 2024 | finance.yahoo.comResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsJanuary 11, 2024 | finance.yahoo.comClosing Bell: Resverlogix Corp flat on Tuesday (RVX)January 4, 2024 | theglobeandmail.comResverlogix Corp. (RVX) Earnings Dates & ReportsDecember 19, 2023 | investing.comResverlogix Corp RVXCFNovember 18, 2023 | morningstar.comMResverlogix Corp RVXNovember 1, 2023 | morningstar.comMResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)October 18, 2023 | theglobeandmail.comResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyOctober 4, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?Why Wall Street Is Betting on These 3 Comeback StocksBy Nathan Reiff | July 12, 2025View Why Wall Street Is Betting on These 3 Comeback StocksD-Wave, SuperQ, and Verge: A New Path Forward for Quantum?By Nathan Reiff | July 28, 2025View D-Wave, SuperQ, and Verge: A New Path Forward for Quantum?RVV, GSD, LTY, and RVX Company DescriptionsGlobal System Dynamics NASDAQ:GSDGlobal System Dynamics, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses its search on the farming and national security sectors, including farming related operations and businesses that support the farming industry. The company was formerly known as Gladstone Acquisition Corporation. Global System Dynamics, Inc. was incorporated in 2021 and is based in Houston, Texas.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Revive Therapeutics CVE:RVVC$0.08 +0.01 (+14.29%) As of 07/22/2019Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.Resverlogix TSE:RVXC$0.10 +0.01 (+11.11%) As of 08/1/2025 03:54 PM EasternResverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
